首页> 外文期刊>Psychogeriatrics : >Effects of Yangxue Qingnao Granules on chronic cerebral circulation insufficiency: A randomized, double-blind, double-dummy, controlled multicentre trial
【24h】

Effects of Yangxue Qingnao Granules on chronic cerebral circulation insufficiency: A randomized, double-blind, double-dummy, controlled multicentre trial

机译:养血清脑颗粒对慢性脑循环功能不全的影响:一项随机,双盲,双模拟,对照的多中心试验

获取原文
获取原文并翻译 | 示例
       

摘要

Background: There is a great deal of interest in traditional Chinese medicine as a treatment for chronic cerebral circulation insufficiency (CCCI). In the present study, we evaluated the efficacy and safety of Yangxue Qingnao Granules (YXQNG) as a monotherapy in patients with CCCI. Methods: From July 2007 to May 2010, 273 patients with CCCI at nine centres in China were randomly assigned to receive either YXQNG with nimodipine placebo (n= 140, 12g/day) or nimodipine with YXQNG placebo (n= 133, 30mg/day) for 8weeks. The primary end points after 8weeks of treatment were changes from baseline in severity of headache, heavy-headed feeling, dizziness and sleep disorder. Results: The mean baseline levels of headache, heavy-headed feeling, dizziness and sleep disorder were comparable between the two groups. Both therapies significantly improved these symptoms after 8weeks of treatment (P < 0.001). Compared with nimodipine therapy, YXQNG resulted in similar reductions in these symptoms. No adverse effects were observed in the YXQNG group. Conclusions: These data demonstrate that YXQNG as a monotherapy were as effective as nimodipine monotherapy in improving the symptoms of CCCI. It is well-tolerated and may have an important place in the management of this condition. Whether a combination of these two medicines will increase therapeutic efficacy deserves further clinical investigation.
机译:背景:中药作为一种治疗慢性脑循环功能不全(CCCI)的药物引起了人们极大的兴趣。在本研究中,我们评估了养血清脑颗粒(YXQNG)作为单药治疗CCCI患者的疗效和安全性。方法:自2007年7月至2010年5月,在中国9个中心的273例CCCI患者被随机分配接受YXQNG联合尼莫地平安慰剂(n = 140,12g /天)或尼莫地平联合YXQNG安慰剂(n = 133,30mg /天) ),持续8周。治疗8周后的主要终点是头痛,重重头疼,头晕和睡眠障碍的严重程度与基线相比有所变化。结果:两组的平均头痛,沉重头疼,头晕和睡眠障碍基线水平相当。两种疗法均在治疗8周后显着改善了这些症状(P <0.001)。与尼莫地平治疗相比,YXQNG导致这些症状的减轻程度相似。 YXQNG组未见不良反应。结论:这些数据表明,YXQNG单一疗法在改善CCCI症状方面与尼莫地平单一疗法一样有效。它具有良好的耐受性,在这种情况的管理中可能占有重要地位。这两种药物的组合是否会提高治疗效果值得进一步的临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号